Core Viewpoint - The company, Brainstorm Cell Therapeutics (脑动极光-B), has seen its stock price increase by over 8% during trading, currently up by 5.87% at HKD 6.67, with a trading volume of HKD 110 million, following the announcement of a strategic partnership with Singapore's Lehe Health Management Group [1] Group 1: Strategic Partnership - The company has entered into a strategic cooperation agreement with Lehe Health Management Group to promote and expand its products in the Singapore market [1] - The collaboration will focus on the localization, system implementation, and personnel training support for cognitive impairment digital therapy products in Singapore [1] - Lehe Health Management Group will utilize its offline stores and member resources to target users for the company's products, providing comprehensive services including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate their resources in products, channels, branding, and technology to jointly explore the Singapore market [1] - The partnership aims to facilitate the entry of the company's products into leading private and public hospitals in Singapore, enhancing the application and popularity of its products within the local healthcare system [1]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has entered a strategic cooperation agreement with Singapore's Lehasiba Health Management Group to promote and expand its digital health products in the Singapore market [1] Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion collaboration in Singapore [1] - Brainstorm Aurora will localize its cognitive impairment digital therapy products, support system implementation, and provide personnel training [1] - Lehasiba will utilize its offline stores and member resources to recommend the company's products to target users and manage the entire service process, including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market [1] - The collaboration aims to promote the company's products into leading private hospitals and public hospital systems in Singapore, enhancing the application and popularity of the products within the local healthcare system [1]

Group 1 - The company, Brainstorm Cell Therapeutics Inc. (06681.HK), has recently entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote product marketing and market expansion in Singapore [1] - The collaboration aims to jointly advance the development of the digital health industry [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources for targeted recommendations and full-service support [2]. - Market expansion efforts will involve integrating resources such as products, channels, brands, and technology to penetrate Singapore's healthcare system, focusing on private and public hospitals [2]. Group 2: Long-term Development Opportunities - This partnership is expected to enhance the company's international presence and expand into Southeast Asia, building on previous experiences in Hong Kong and Macau [3]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and expedite product integration into local medical institutions, thereby broadening its market reach [3].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote and expand its digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources to recommend the products to target users and provide full-service support [2]. - Market expansion collaboration will involve integrating resources such as products, channels, brands, and technology to jointly develop the Singapore market, focusing on introducing the company's products into leading private and public hospitals [2]. Group 2: Long-term Development Opportunities - The cooperation is expected to deepen the company's international presence and expand into overseas markets, marking the official launch of its Southeast Asia market strategy, building on prior experiences in Hong Kong and Macau [3]. - This partnership is anticipated to enhance the company's brand influence and commercial network in the digital healthcare sector, facilitating quicker product integration into local medical institutions and diversifying into various digital health management markets [3].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion in Singapore, leveraging the local government's initiatives for early screening and health management for cognitive disorders [1]. - The company will localize its cognitive disorder digital therapy products for the Singapore market, while Natural Health Solutions will utilize its network to recommend these products to target users [2]. Group 2: Market Expansion - The collaboration aims to integrate resources such as products, channels, and technology to penetrate the Singapore healthcare system, particularly targeting private and public hospitals [2]. - This partnership marks the company's formal entry into the Southeast Asian market, building on its previous experiences in Hong Kong and Macau [3]. Group 3: Long-term Opportunities - The cooperation is expected to enhance the company's international presence and brand influence, allowing it to export its digital therapy expertise to other supportive regions [3]. - The partnership will strengthen the company's authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 訂立戰略合作協議以拓展新加坡市場及推動國際化佈局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者瞭解本集團最新業務發展情況。 根據協議，雙方合作主要包括以下內容：(I)產品推廣合作：本公司負責認知障礙 數字療法產品在新加坡的本土化適配、系統落地及人員培訓支持；萊賀思寶將依 託其全部線下門店及會員資源，向目標用戶定向推薦本公司產品，並負責全流程 服務，包括產品介紹、試用引導、購買轉化及售後支持。(II)市場拓展協同：雙方 整合產品、渠道、品牌與技術等資源，共同開拓新加坡市場，重點推動本公司產 品進入新加坡頭部私立醫院及公立醫院體系，提升產品在當地醫療系統中的應用 與普及。 ...

Core Viewpoint - The brain-machine interface sector is experiencing a surge in stock prices following the release of a new regulatory framework by the National Medical Products Administration (NMPA) in China, which includes a list of prioritized high-end medical devices for approval [1] Group 1: Stock Performance - Heartway Medical-B (06609) saw a price increase of 12.22%, reaching 54 HKD [1] - Brain Dynamics-B (06681) rose by 7.78%, trading at 6.79 HKD [1] - Nanjing Panda Electronics (00553) increased by 7.14%, with a price of 4.65 HKD [1] Group 2: Regulatory Developments - On December 26, the NMPA published the "Priority Approval List for High-End Medical Devices (2025 Edition)," which includes eight products, such as implantable brain-machine interface devices [1] - The list outlines the technical parameters and expected uses of the products [1] - The NMPA is actively promoting faster and better market entry for brain-machine interface devices through a dedicated working meeting [1] Group 3: Market Outlook - Guotai Junan Securities notes that recent policies have shown strong support for innovation in medical devices [1] - The brain-machine interface sector has diverse application scenarios and rich product and research pathways, indicating significant future potential [1] - With the support of product registration and medical insurance policy initiatives, commercialization is expected to accelerate [1]

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a collective surge, with notable increases in stock prices for several companies [1] - Heartway Medical-B saw a rise of over 12%, while Brain Dynamics-B and Nanjing Panda Electronics both increased by over 7% [1] - The Fifth Frontier Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo commenced on December 28, marking the official launch of the "Guangdong-Hong Kong-Macau Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" [1] Group 2 - Heartway Medical-B's latest price is 54.000, with a total market capitalization of 2.069 billion and a year-to-date increase of 146.01% [2] - Brain Dynamics-B's latest price is 6.790, with a total market capitalization of 8.598 billion and a year-to-date increase of 110.87% [2] - Nanjing Panda Electronics' latest price is 4.650, with a total market capitalization of 4.249 billion and a year-to-date increase of 35.57% [2] - Brainhole Technology's latest price is 0.230, with a total market capitalization of 0.0184 billion and a year-to-date increase of 1.77% [2] - Microneuroscience's latest price is 11.000, with a total market capitalization of 6.336 billion and a year-to-date increase of 30.18% [2]

（文章来源：每日经济新闻） 每经AI快讯，脑动极光-B(06681.HK)涨超3%，截至发稿，涨3.33%，报6.51港元，成交额4833.44万港 元。 ...